Repetitive Profound Thrombocytopenia After Treatment with Tirofiban: A Case Report

被引：0
作者：
Beyhan Eryonucu
Mustafa Tuncer
Reha Erkoc
机构：
[1] Yüzüncü Yil University,Cardiology Department, Medical Faculty
[2] Yüzüncü YilÜniversitesi,undefined
[3] Tip Fakültesi Kardiyoloji AD,undefined
来源：
Cardiovascular Drugs and Therapy | 2004年 / 18卷
关键词：
thrombocytopenia; tirofiban;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The GPIIb/IIIa inhibitors are used in the acute coronary syndromes and interventional cardiology as antiplatelet agents. These drugs induce thrombocytopenia in approximately 1–5% of patients. Thrombocytopenia is rapid in onset and antibody mediated. Abciximab is associated with higher incidence of thrombocytopenia than eptifibatide and tirofiban. Profound thrombocytopenia has reportedly been an issue with abciximab, but not with tirofiban. We reported a case of acute profound thrombocytopenia due to on tirofiban treatment in the same patient at two different times.
引用
收藏
页码：503 / 505
页数：2
相关论文
共 32 条
  • [1] Karvouni E(2003)Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J Am Coll Cardiol 41 26-32
  • [2] Katritsis DG(2002)Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials Lancet 359 189-198
  • [3] Ioannidis J(2004)Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors Curr Hematol Rep. 3 143-147
  • [4] Boersma E(2000)Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis Am Heart J 140 206-211
  • [5] Harrington RA(2004)Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation 109 2203-2206
  • [6] Moliterno DJ(2000)Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and re-treatment Am Heart J 139 S38-S45
  • [7] Abrams CS(1981)A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 239-245
  • [8] Cines DB(2002)Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa Blood 100 2071-2076
  • [9] Dasgupta H(2002)Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximabcoated platelets Blood 99 2054-2059
  • [10] Blankenship JC(2001)Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization New Engl J Med 344 1888-1894
1234